Functional Dyspepsia: PDS vs EPS, Rome IV Criteria, and Evidence-Based Treatment Guide

1. Pathophysiology: What Goes Wrong in the Upper Gut

Functional dyspepsia is not a single disease with a single mechanism. It is a heterogeneous syndrome in which multiple overlapping pathophysiological disturbances converge to produce upper abdominal symptoms in the absence of identifiable structural or biochemical disease. Understanding these mechanisms informs why different patients respond to different treatments.

Impaired Gastric Accommodation (Fundus Relaxation Failure)

Under normal conditions, the gastric fundus relaxes reflexively during eating — a vagally mediated process that increases gastric volume by 500–1000 mL while maintaining intragastric pressure. This accommodation reflex depends on nitric oxide (NO)-mediated inhibition and 5-HT1A receptor signaling.

In approximately 40% of FD patients, this accommodation reflex is impaired. The fundus fails to relax adequately, causing rapid antral distension and accelerated meal distribution toward the antrum. The result is early satiety and postprandial fullness — the hallmarks of PDS. Scintigraphic studies confirm that impaired accommodation correlates directly with the severity of meal-induced symptoms.

This is the mechanistic basis for using fundus-relaxing drugs such as buspirone (5-HT1A agonist) and mirtazapine in PDS — both enhance NO-mediated fundal relaxation and have demonstrated symptom benefit in randomized trials.

Visceral Hypersensitivity and CCK Hypersensitivity

A substantial subset of FD patients exhibit heightened perception of normal mechanical stimuli (gastric distension) and chemical stimuli (acid, fat, CCK). This visceral hypersensitivity involves sensitization at multiple levels: peripheral afferent neurons, spinal dorsal horn circuits, and supraspinal (thalamo-cortical) processing.

Cholecystokinin (CCK) is a key mediator. Released in response to dietary fat and protein entering the duodenum, CCK slows gastric emptying and enhances afferent signaling. In FD patients, the CCK response is disproportionate — even low-fat meals trigger exaggerated symptoms. Studies using the CCK-A antagonist loxiglumide have confirmed that blocking CCK signaling reduces FD symptoms, validating this pathway.

Duodenal Microinflammation and Eosinophilia

Landmark work by Jan Tack, Nicholas Talley, and others established that a significant proportion of FD patients have subtle but real immune activation in the duodenal mucosa — without meeting criteria for eosinophilic gastroenteritis. Duodenal eosinophil counts are elevated in FD compared to healthy controls, and mast cell infiltration is also increased.

This microinflammation is thought to sensitize submucosal afferent nerve endings, lowering the threshold for pain and discomfort. The triggers include prior gastrointestinal infection (post-infectious FD), dietary antigens, and possibly altered microbiome composition. Notably, duodenal eosinophilia correlates with epigastric pain severity, linking it more strongly to EPS.

Gut-Brain Axis Amplification

Central processing of visceral signals is fundamentally altered in FD. Functional neuroimaging reveals abnormal activation of the anterior insula, anterior cingulate cortex, and amygdala in response to gastric stimulation — regions involved in interoceptive awareness, affect, and pain modulation.

The bidirectional gut-brain axis means that psychological states (anxiety, depression, early life stress) directly amplify visceral signaling, while persistent gut symptoms drive CNS sensitization. This is why FD shows high comorbidity with anxiety disorders (up to 40%) and why central neuromodulators (TCAs, SSRIs, buspirone) are clinically effective — they work on the brain side of a brain-gut problem.

2. Rome IV Subtypes: Classifying FD for Targeted Treatment

The Rome IV classification (2016) refined our understanding of FD by establishing two clinically and mechanistically distinct subtypes. Accurate subtype classification guides treatment selection because the mechanistic basis — and therefore the optimal pharmacological target — differs between them.

Postprandial Distress Syndrome (PDS)

Diagnostic criteria (Rome IV): One or both of the following at least 3 days per week for the last 3 months (onset ≥6 months ago), with no evidence of structural disease:

• Bothersome postprandial fullness — occurring after ordinary-sized meals, sufficient to impact usual activities
• Bothersome early satiation — inability to finish an ordinary-sized meal

PDS is the more common subtype, affecting roughly 60–70% of FD patients. Its primary drivers are impaired gastric accommodation, delayed gastric emptying (present in ~30–40% of PDS patients), and antral hypersensitivity. Nausea is a common accompanying symptom, as is upper abdominal bloating.

Treatment is primarily directed at improving gastric motility and accommodation: prokinetics (itopride, metoclopramide), fundus-relaxing agents (buspirone, mirtazapine), and acotiamide in Japan. PPIs are less effective for pure PDS.

Epigastric Pain Syndrome (EPS)

Diagnostic criteria (Rome IV): All of the following, at least 1 day per week:

• Bothersome epigastric pain or burning
• Pain is intermittent and not generalized or located only in other abdominal regions
• Not relieved by defecation or passage of flatus (distinguishing it from IBS)
• Not fulfilling criteria for gallbladder or sphincter of Oddi disorders

EPS is more strongly driven by visceral hypersensitivity, duodenal acid hypersensitivity, and duodenal microinflammation. Epigastric burning specifically suggests acid as a contributing factor, which is why PPIs show more benefit in EPS than PDS. Low-dose TCAs address the neuromodulatory component.

Overlap with IBS and GERD

The Rome IV diagnostic framework acknowledges that FD subtypes are not mutually exclusive: PDS and EPS co-occur in approximately 30–50% of FD patients. Additionally:

• FD-IBS overlap: Up to 40% of FD patients also meet Rome IV criteria for IBS. This overlap likely reflects shared mechanisms — gut-brain axis sensitization, mucosal microinflammation, altered motility patterns. These patients tend to have more severe symptoms and greater psychosocial comorbidity.
• GERD overlap: Heartburn and regurgitation can coexist with FD, complicating diagnosis. The diagnostic challenge is that PPIs may improve GERD-related symptoms without addressing core FD pathology. Careful symptom mapping is essential.

3. H. pylori and Functional Dyspepsia

Helicobacter pylori infection occupies a unique position in FD management: it is the one potentially reversible etiology that bridges organic and functional disease. The 2015 Kyoto Global Consensus reclassified H. pylori-associated dyspepsia as a distinct entity, acknowledging that successful eradication can produce lasting symptom resolution.

Prevalence and Correlation

H. pylori prevalence in FD patients varies markedly by region — ranging from 20–30% in North America and Western Europe to 60–80% in parts of Asia, Africa, and South America. The correlation between H. pylori positivity and FD symptoms is real but modest: H. pylori causes chronic active gastritis in virtually all infected individuals, and the inflammatory milieu this produces can drive both mucosal hypersensitivity and altered motility.

Eradication Response Rates

The landmark 2017 Cochrane meta-analysis by Ford et al. pooled data from 21 randomized trials (n = 3,566) and found H. pylori eradication superior to placebo for FD symptom relief, with a relative risk of remaining dyspeptic of 0.91 (95% CI 0.88–0.94). This translates to an NNT of approximately 14 — meaning 1 in every 14 treated patients achieves sustained benefit attributable to eradication alone.

While this NNT may seem modest, eradication carries additional benefits: it reduces gastric cancer risk, prevents peptic ulcer disease, and in responders, provides durable relief without ongoing medication. The current ACG, BSG, and European guidelines all recommend H. pylori test-and-treat as a first-line strategy in uninvestigated dyspepsia.

Why Some Patients Don't Respond

Approximately 86% of H. pylori-positive FD patients will not experience meaningful symptom relief despite successful eradication. Several explanations account for non-response:

• The FD pathophysiology in non-responders is primarily driven by impaired accommodation or visceral hypersensitivity — mechanisms independent of H. pylori gastritis
• Antibiotic-related gut microbiome disruption may transiently worsen GI symptoms
• Symptomatic improvement may be delayed — some studies show benefit emerging 6–12 months after eradication
• Concurrent GERD or IBS pathology may obscure FD-specific improvement

Retesting Strategy

Confirmation of eradication is recommended 4–6 weeks after completing therapy (and at least 2 weeks after stopping PPIs) using urea breath test (UBT) or stool antigen test. In patients with persistent symptoms after confirmed eradication, the diagnosis of H. pylori-negative FD is established and treatment pivots to acid suppression, neuromodulation, and motility agents.

For eradication failures, second-line regimens (bismuth quadruple therapy or levofloxacin-based triple therapy) are used, ideally guided by antibiotic susceptibility testing where available.

4. Medical Treatment: From Acid Suppression to Neuromodulation

No single pharmacological agent works uniformly across all FD patients, reflecting the mechanistic heterogeneity of the condition. Treatment selection should be guided by subtype (PDS vs EPS), symptom severity, and response to prior therapies.

PPIs and H2 Blockers

Proton pump inhibitors (PPIs) are effective in EPS, particularly when epigastric burning predominates. A 2006 Cochrane meta-analysis found PPIs superior to placebo with an NNT of approximately 9 for EPS-predominant symptoms. The mechanism involves reduction in duodenal acid load, which directly reduces afferent sensitization and CCK-mediated responses.

Standard doses (e.g., omeprazole 20 mg, pantoprazole 40 mg, esomeprazole 40 mg) for 4–8 weeks are the typical initial trial. In PDS without burning, PPIs show limited benefit — the dominant mechanisms (impaired accommodation, delayed emptying) are not acid-dependent.

H2 receptor antagonists (famotidine, ranitidine equivalents) have moderate evidence in FD, with meta-analyses showing benefit over placebo. They are less potent than PPIs but may be appropriate for milder EPS, patients who experience rebound acid hypersecretion with PPI cessation, or those intolerant of PPIs. Nocturnal acid breakthrough is better controlled with H2 blockers than PPIs.

Low-Dose Tricyclic Antidepressants: Amitriptyline and Nortriptyline

Low-dose TCAs represent the most robustly evidenced neuromodulatory approach in FD. They work via multiple mechanisms relevant to the gut-brain axis: blockade of sodium channels in enteric neurons, antagonism of histamine H1 receptors (reducing visceral sensitization), and serotonin/norepinephrine reuptake inhibition.

The HAPPINESS trial (van Kerkhoven et al., 2008; later replicated) demonstrated that amitriptyline 25 mg nightly significantly reduced epigastric pain and overall FD severity compared to placebo in EPS-predominant patients (NNT approximately 6). Effect size was largest in those without delayed gastric emptying, suggesting the primary mechanism is neuromodulatory rather than prokinetic.

Key clinical points for TCA use in FD:

• Doses are subtherapeutic for depression (10–50 mg) — communicate this clearly to patients to avoid non-adherence based on stigma
• Anticholinergic side effects (dry mouth, constipation, urinary hesitancy) are dose-dependent; start at 10–25 mg and titrate slowly
• Nortriptyline has a more favorable side-effect profile than amitriptyline due to less anticholinergic activity
• Allow 4–6 weeks for full effect assessment; a trial of 3–6 months is reasonable before discontinuation

Acotiamide (Japan): Prokinetic Innovation for PDS

Acotiamide (Acofide) represents a major advance in PDS-targeted pharmacology. Its mechanism combines: (1) acetylcholinesterase inhibition — increasing acetylcholine at the neuromuscular junction to enhance gastric contractions, and (2) antagonism of muscarinic M1/M2 autoreceptors on cholinergic neurons — reducing the inhibitory feedback that would otherwise limit acetylcholine release.

The pivotal phase III trial (Matsueda et al., 2012, n=892) demonstrated that acotiamide 100 mg three times daily significantly improved postprandial fullness, early satiety, and upper abdominal bloating compared to placebo in PDS patients (response rate 52.2% vs 34.8%, p<0.001). The drug is well tolerated with minimal systemic absorption.

Availability: Acotiamide is approved in Japan (2013) and India for FD. As of 2026, it remains unapproved in the US and EU pending further Phase III data, though investigational use and international access pathways exist.

Buspirone for Impaired Accommodation

Buspirone, a 5-HT1A partial agonist primarily used for generalized anxiety disorder, has demonstrated significant enhancement of gastric accommodation in both healthy subjects and FD patients. A 2012 randomized trial by Tack et al. showed that buspirone 10 mg three times daily significantly reduced postprandial fullness, early satiation, and upper abdominal bloating versus placebo in PDS.

Buspirone's anxiolytic properties may additionally benefit the subset of FD patients with prominent anxiety comorbidity. It is generally well tolerated, with dizziness and nausea as main side effects at standard doses.

Mirtazapine (15–30 mg nightly) is another option for PDS patients with significant weight loss and nausea — it enhances gastric accommodation via 5-HT3 antagonism and 5-HT1A agonism, while simultaneously stimulating appetite and improving sleep.

5. Diet, Lifestyle, and Mind-Gut Therapy

Non-pharmacological approaches are underutilized in FD management but carry meaningful evidence, particularly for patients who prefer to minimize medication use or have not responded adequately to pharmacotherapy.

Dietary Fat and CCK-Mediated Triggers

Dietary fat is the single most potent CCK secretagogue, and CCK hypersensitivity is a central mechanism in FD visceral hypersensitivity. Controlled studies demonstrate that high-fat meals produce significantly greater symptoms in FD patients compared to low-fat isocaloric meals, and this difference is abolished by CCK receptor blockade.

Fat reduction is therefore the highest-yield dietary intervention in FD — more consistently supported by mechanistic and clinical evidence than any other dietary change. Practical guidance includes:

• Reduce total dietary fat to <30% of calories during symptom-active periods
• Prioritize lean protein sources and complex carbohydrates
• Limit fried foods, fatty meats, and high-fat dairy
• Use olive oil in moderation rather than saturated fats, which slow gastric emptying more than unsaturated fats

Small Frequent Meals and Eating Behaviors

Small, frequent meals (4–6 per day rather than 2–3 large meals) reduce peak fundic distension and minimize the stimulus for impaired accommodation. This is particularly relevant in PDS. Additional evidence-backed behavioral modifications:

• Slow eating: Eating quickly increases air swallowing and accelerates gastric filling rates — both worsen symptoms
• Spicy food: Capsaicin can desensitize TRPV1 channels long-term but acutely worsens visceral hypersensitivity in many FD patients — individual response varies
• Caffeine and alcohol: Delay gastric emptying and may lower the symptom threshold
• Carbonated beverages: Increase gas and gastric distension — limit in PDS

Low-FODMAP Diet: Partial Evidence

The low-FODMAP diet was developed for IBS and has strong evidence in that condition. In FD, the evidence is less robust — two small randomized trials show modest benefit, primarily in the FD-IBS overlap group. Given the significant overlap between FD and IBS (up to 40% of FD patients), a trial of low-FODMAP restriction for 4–6 weeks is reasonable in patients with coexisting bloating, altered bowel habits, and FD symptoms, with reintroduction to identify specific triggers.

Gut-Directed Hypnotherapy

Gut-directed hypnotherapy (GDH) has the strongest psychological therapy evidence base in functional GI disorders. The Manchester protocol, originally developed for IBS, has been adapted for FD with promising results. Calvert et al. (2002) demonstrated in a randomized trial that hypnotherapy produced significantly greater symptom improvement than supportive therapy plus ranitidine in FD patients — with benefits maintained at 1-year follow-up.

GDH mechanisms in FD include reduction in visceral hypersensitivity (documented by increased gastric pain thresholds), normalization of autonomic tone, reduction in anxiety-driven gut-brain amplification, and improvements in health-related quality of life. Access remains limited due to therapist availability and cost, but digital and audio-based delivery formats are expanding reach.

Cognitive Behavioral Therapy (CBT)

CBT adapted for functional GI disorders targets catastrophizing, hypervigilance toward GI sensations, avoidance behaviors, and the symptom-anxiety cycle. A meta-analysis of psychological therapies in functional dyspepsia (including CBT and psychotherapy) showed significant superiority over control conditions (RR 0.73, NNT approximately 5). CBT is particularly effective in FD patients with prominent health anxiety, symptom catastrophizing, or early life adversity.

Key Evidence Base: Landmark FD Studies

Functional Dyspepsia Management Protocol: 8 Steps

Supplements With Mechanistic Relevance to FD

The following supplements have relevant mechanisms for FD management. They are not substitutes for medical evaluation and treatment. Always consult your physician before adding supplements, especially if taking prescription medications.

Related Articles